Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2017 / Article

Corrigendum | Open Access

Volume 2017 |Article ID 5923818 | 1 page | https://doi.org/10.1155/2017/5923818

Corrigendum to “Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo

Received10 May 2017
Accepted24 May 2017
Published20 Aug 2017

In the article titled “Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo” [1], an acknowledgment should be added as follows:

Acknowledgments

This publication was supported by the Wrocław Centre of Biotechnology, programme The Leading National Research Centre (KNOW) for years 2014-2018.

References

  1. K. Marycz, K. A. Tomaszewski, K. Kornicka et al., “Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 9785890, 19 pages, 2016. View at: Publisher Site | Google Scholar

Copyright © 2017 Krzysztof Marycz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

521 Views | 211 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.